Payment overview · 2025
General Payments
$349.48
15 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Anthony Aranda, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COTTONWOOD, AZ · NPI 1922065127
Verified facts
What the public records show
CMS Open Payments records show Michael Anthony Aranda, D.O. received $349.48 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 71.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $250.27 | 71.6% | 10 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.43 | 20.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.21 | 4.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.57 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $349.48 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.25 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $130.16 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $70.43 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 81 |
| Lisinopril | Lisinopril | 252 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 72 |
| Gabapentin | Gabapentin | 184 | 55 |
| Losartan Potassium | Losartan Potassium | 163 | 54 |
| Metformin Hcl | Metformin Hcl | 157 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 43 |
| Omeprazole | Omeprazole | 126 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 32 |
| Furosemide | Furosemide | 114 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 31 |
| Trazodone Hcl | Trazodone Hcl | 109 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 27 |
| Meloxicam | Meloxicam | 104 | 34 |
| Montelukast Sodium | Montelukast Sodium | 102 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 19 |
| Simvastatin | Simvastatin | 92 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 24 |
| Eliquis | Apixaban | 82 | 19 |
| Potassium Chloride | Potassium Chloride | 71 | 30 |
| Glimepiride | Glimepiride | 70 | 22 |
| Tramadol Hcl | Tramadol Hcl | 70 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 23 |
| Allopurinol | Allopurinol | 65 | 17 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Memantine Hcl | Memantine Hcl | 61 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 45 |
| Farxiga | Dapagliflozin Propanediol | 55 | 16 |
| Propranolol Hcl | Propranolol Hcl | 55 | 14 |
| Carvedilol | Carvedilol | 53 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Prednisone | Prednisone | 52 | 29 |
| Azithromycin | Azithromycin | 48 | 43 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Lorazepam | Lorazepam | 45 | 15 |
| Celecoxib | Celecoxib | 43 | 11 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 15 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 15 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 29 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 36 | 12 |
| Spironolactone | Spironolactone | 35 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | 11 |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 16 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.48 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, KISUNLA, NUZYRA, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error